This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead (GILD) obtains positive opinion from the CHMP for its MAA for CAR T therapy, axicabtagene ciloleucel, as a treatment for DLBCL and PMBCL.
Will a Trade War With China Wreak Havoc in US Healthcare?
by Nitish Marwah
It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.
Amgen Announces Top-Line Data From Remicade Biosimilar Study
by Zacks Equity Research
Amgen (AMGN) presents top-line results from a late-stage study evaluating its biosimilar version of Remicade. Data shows that there was no clinically meaningful difference between the two products.
AstraZeneca/Merck's Lynparza Betters Survival in Phase III
by Zacks Equity Research
AstraZeneca (AZN) and Merck's (MRK) Lynparza significantly delays disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.
Merck's Keytruda Under FDA Review for Advanced Melanoma
by Zacks Equity Research
Merck (MRK) announces acceptance of its sBLA for Keytruda by the FDA for the treatment of patients with high-risk stage III melanoma.
Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection
by Zacks Equity Research
Gilead's (GILD) HIV portfolio gets a further boost with the European Commission's approval of Biktarvy for HIV-1 infection.
Merck (MRK) Presents New Data from Januvia Diabetes Studies
by Zacks Equity Research
Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.
Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announces that the FDA accepts its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo.
Merck (MRK) Stock Up So Far This Year on Keytruda Strength
by Zacks Equity Research
Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Incyte (INCY) Announces Positive Results on Jakafi for GVHD
by Zacks Equity Research
Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.
TESARO (TSRO) Stock Up on Rumors of Buyout Offer From Roche
by Zacks Equity Research
Shares of TESARO (TSRO) rise on speculation of an acquisition bid from Roche.
Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx
by Zacks Equity Research
The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.
ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer
by Zacks Equity Research
With ImmunoGen's (IMGN) lead pipeline candidate, mirvetuximab soravtansine getting Fast Track designation in the United States, its development and review are likely to get expedited.
Bristol-Myers Posts Data on Empliciti, China Approves Opdivo
by Zacks Equity Research
Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.
Top Ranked Income Stocks to Buy for June 15th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, June 15th:
Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication
by Zacks Equity Research
Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.
Merck (MRK): Moving Average Crossover Alert
by Zacks Equity Research
Merck & Co., Inc. (MRK) is looking like an interesting pick from a technical perspective
Top Ranked Income Stocks to Buy for June 14th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, June 14th:
Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.
Six Flags Entertainment, Thomson Reuters, Toyota Motor, China Petroleum & Chemical and Merck highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Six Flags Entertainment, Thomson Reuters, Toyota Motor, China Petroleum & Chemical and Merck highlighted as Zacks Bull and Bear of the Day
Top Ranked Income Stocks to Buy for June 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, June 12th:
AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.
Amgen's (AMGN) Prolia Gets Label Expansion Approval in Europe
by Zacks Equity Research
Amgen (AMGN) announces approval for its regulatory application seeking label expansion for Prolia in Europe.
Mega Caps Are Soaring in June: 3 Top-Ranked Stocks on Sale
by Sweta Killa
Given the encouraging mega-cap trends, investors should stuff stocks on the cheap for outsized gains in the coming weeks.
Dow 30 Stock Roundup: UnitedHealth Hikes Quarterly Dividend by 20%, Microsoft Confirms GitHub Buyout
by Swarup Gupta
The Dow enjoyed a week of steady gains with trade concerns largely taking a backseat.